Worldwide Liquid Biopsy (LBx) Market Forecasted to Grow at 27% p.a., Reaching ~$17B by 2031 – Market Report by DeciBio Consulting LLC

______________________________________________________________________

Los Angeles, CA
March 24th, 2026

‍

Los Angeles, CA – DeciBio Consulting has released the fourth edition of its Oncology Liquid Biopsy Market Report, offering updated global estimates of how liquid biopsy technologies are being applied across clinical and pharmaceutical research settings.

The report draws on in-depth interviews with more than 30 experts in the field, including medical oncologists, biopharma researchers, technology providers, and other key healthcare stakeholders to capture the dynamic and evolving liquid biopsy market. Participants were selected globally to reflect diverse regulatory and reimbursement environments, including experts from countries such as the U.S., Spain, Italy, France, the U.K., Germany, Japan, and China.

The 4th Edition Oncology Liquid Biopsy Report explores clinical adoption across the patient care continuum, from genomic profiling and minimal residual disease (MRD) and recurrence monitoring to early cancer detection. It also highlights how biopharma organizations are leveraging liquid biopsy in clinical trials, including for exploratory research. Interviewees discussed current trends in technology adoption, anticipated developments through 2026 and beyond, and key market drivers and barriers shaping utilization.

“We’re seeing global enthusiasm for liquid biopsy.  Despite rapid growth for several years, liquid biopsy adoption in most markets and for most applications remains under-penetrated, representing significant opportunity for sustained growth.  Realizing this market potential will require significant investments in implementing new testing workflows, developing robust commercial channels, establishing innovative reimbursement models, and educating stakeholders throughout the ecosystem,” says Andrew Aijian, Senior Partner at DeciBio. 

By combining expert input with company-specific data on testing volumes and customer behavior, the report quantifies real-world adoption across multiple dimensions, including geography, testing access models (in-house vs. send-out), cancer type (e.g., breast, lung, colorectal, prostate, and others), and perceptions of competitive dynamics. These insights help stakeholders across the commercial ecosystem identify market opportunities and align strategic investments with global momentum.

Example Liquid Biopsy Companies Mentioned:

• AmoyDx
• Berry Oncology
• BillionToOne
• Burning Rock 
• Caris Life Sciences
• DELFI Diagnostics
• Exact Sciences
• Foundation Medicine
• Freenome
• Genetron Health
• Geneseeq Technology 
• GRAIL
• Guardant Health
• Illumina
• LabCorp / PGDx
• Tempus
• Thermo Fisher Scientific
• Natera
• NeoGenomics 
• Personalis
• Roche
• SeekIn
• Sophia Genetics

‍

Market Drivers

The breadth of LBx applications highlights a diverse set of growth opportunities across the care continuum and creates space for competitors to expand and differentiate their portfolios. Accelerating companion diagnostics approvals across a broad range of solid tumors continues to pave the way for adoption, especially in ex-U.S. markets. 

Interventional studies are further validating the value of LBx in MRD-directed care, both in informing clinical decision-making and enabling more efficient trial design and patient stratification for biopharma stakeholders. While reimbursement remains an evolving dynamic, particularly in ex-U.S. markets, momentum is building in surveillance and MRD use cases, unlocking significant long-term potential given the ability to perform repeat, longitudinal testing.

Additionally, reimbursement gains for early cancer detection (e.g., Guardant Shield) continue to underscore the importance of LBx in cancer screening, with sustained investment focused on defining optimal implementation pathways and demonstrating clinical utility at scale for multi-cancer early detection. 

‍

Market Moderators

Despite strong clinical enthusiasm, regulatory and reimbursement frameworks are advancing more gradually overall, reinforcing a pattern of incremental adoption rather than rapid market expansion. The relatively high cost of LBx testing remains a key barrier, impacting both clinical utilization, where optimal testing paradigms are still being established, and biopharma adoption, where the demand for high-resolution data must be balanced against cost considerations. Furthermore, while early cancer detection initiatives are extensive and represent a significant long-term opportunity, they are accompanied by risks: challenges related to demonstrating clinical utility at scale, particularly in asymptomatic populations, may emerge as these tests are deployed more broadly, potentially tempering near-term market growth.

‍

The Liquid Biopsy Report complements DeciBio’s expanding suite of genomic profiling products, including the Europe Oncology Genomics Tracker (launched this year) and the U.S. Oncology Genomics Tracker.

• Learn more about the Europe Oncology Genomics Tracker: 
• https://www.decibio.com/product/europe-oncology-genomics-tracker
• Learn more about the U.S. Oncology Genomics Tracker: 
• https://www.decibio.com/product/u-s-oncology-genomics-tracker

The EU Oncology Genomics Tracker (covering the U.K., Germany, Italy, France, and Spain) is updated biannually, while the U.S. Oncology Genomics Tracker is released quarterly. Both provide detailed analyses of clinical genomic testing trends, including genomic profiling, MRD and recurrence monitoring, and treatment response tracking across their respective regions.

‍

About DeciBio:

DeciBio Consulting (www.decibio.com) is the leading strategy consulting, market intelligence, and SaaS firm dedicated to accelerating innovation in precision medicine.

Headquartered in Los Angeles, California, DeciBio serves a global base of clients and customers, ranging from startups to Fortune 500 healthcare corporations. DeciBio offers advisory services for growth planning, market and opportunity assessment, product and portfolio strategy, voice-of-customer feedback, technology assessment, and commercial due diligence.